Federal officials approved a new pain pill designed to eliminate the risks of addiction and overdose associated with opioid ...
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX stock over the recent years has been far from consistent, and has largely ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
Discover the latest trends in the business world, from Barnes and Noble's growth fueled by BookTok to the FDA's approval of a new nonopioid pain medication.
Investor's Business Daily on MSN1h
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid PainkillerVertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback